ArticleBeyoglu eye journal2025
Thermal Pulsation Therapy (Lipiflow®): A Retrospective Analysis of Its Impact on Meibomian Gland Dysfunction and Dry Eye Disease.
Article in Beyoglu eye journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LipiFlow and the Transformation of Therapeutic Meibomian Gland Expression into Routine Clinical Practice.Ophthalmology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The study aimed to evaluate the short-term effects of thermal pulsation therapy on dry eye parameters and meibomian gland dysfunction (MGD) in patients with evaporative dry eye. Methods: A retrospective, single-center study included 250 eyes of 125 symptomatic patients with evaporative dry eye disease (DED) due to MGD. Patients received a single 12-min thermal pulsation therapy (LipiFlow®) (TearScience Inc., Morrisville, NC, USA). Before and at 1 and 6 months after treatment, the presence of DED and MGD was evaluated using the Schirmer-I test, tear break-up time (TBUT), oxfordstaining score, and meibomian gland secretion (MGS) score. Subjective dry eye complaints were measured using the ocular surface disease index (OSDI) score. Results: The LipiFlow treatment improved both clinical signs (Schirmer I test, Oxford staining score, MGS score, and TBUT, respectively, p=0.000, p=0.000, p=0.000, p=0.000) and symptoms (OSDI scores p=0.000) up to 1 month post-treatment. While TBUT and MGS scores (respectively p=0.008, p=0.035) continued to improve until the 6 Conclusion: It has been observed that single-session thermal pulsation treatment provides improvement in MGD and dry eye parameters up to 6 months and decreases in OSDI scores, indicating subjective complaints of patients. This treatment is thought to be an effective treatment option in evaporative DED secondary to MGD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.